Advertisement

EPMA Journal

, Volume 10, Issue 3, pp 307–316 | Cite as

Association among resistin, adenylate cyclase-associated protein 1 and high-density lipoprotein cholesterol in patients with colorectal cancer: a multi-marker approach, as a hallmark of innovative predictive, preventive, and personalized medicine

  • Marija MihajlovicEmail author
  • Ana Ninic
  • Miron Sopic
  • Milica Miljkovic
  • Aleksandra Stefanovic
  • Jelena Vekic
  • Vesna Spasojevic-Kalimanovska
  • Dejan Zeljkovic
  • Bratislav Trifunovic
  • Zeljka Stjepanovic
  • Aleksandra Zeljkovic
Research
  • 20 Downloads

Abstract

Background

Elevated concentrations of resistin have been reported in colorectal cancer (CRC), but its interactions with adenylate cyclase-associated protein 1 (CAP-1) are largely unexplored. We investigated resistin plasma concentration, peripheral blood mononuclear cells (PBMCs) resistin messenger ribonucleic acid (mRNA), and CAP-1 mRNA levels in CRC patients, as well as the impact of resistin gene polymorphism rs1862513 on the examined markers. We also explored associations of resistin with high-density lipoprotein cholesterol (HDL-C) and predictive potential of our parameters for CRC.

Methods

Eighty-six patients with CRC and 75 healthy adults were included. Commercial ELISA kit was used for obtaining resistin’s concentrations, while polymerase chain reaction (PCR) method was applied for evaluation of resistin and CAP-1 mRNA levels and rs1862513 polymorphism.

Results

Plasma resistin and CAP-1 mRNA levels were higher in CRC patients (p < 0.001 and p < 0.05, respectively), while resistin mRNA levels were lower (p < 0.001). Negative association existed among plasma resistin and HDL-C concentrations (ρ = − 0.280; p < 0.05). A model including age, body-mass index, HDL-C, low-density lipoprotein cholesterol (LDL-C), and plasma resistin concentrations as independent predictors of CRC showed very good diagnostic accuracy (AUC = 0.898). We found no associations of rs1862513 with the examined markers.

Conclusions

Our study demonstrated increased plasma resistin and CAP-1 mRNA levels, implying their possible interaction in CRC. The association among plasma resistin and HDL-C might indicate that HDL-C is involved in alterations of resistin’s secretion process. As a hallmark of personalized medicine, multi-marker approach in determination of resistin-related parameters might be useful for prediction and prevention of CRC development.

Keywords

Resistin Adenylate cyclase-associated protein 1 High-density lipoprotein cholesterol Paraoxonase-1 activity Colorectal cancer Predictive preventive personalized medicine 

Notes

Authors’ contribution

MM (corresponding author) performed laboratory measurements, statistical analysis, and wrote the first draft of the manuscript. AN, MS, MM, and AS contributed to experimental design and participated in laboratory analyses. DZ, BT, and ZS were involved in protocol development, patient recruitment, and data acquisition. JV and VSK provided intellectual guidance and critically reviewed the manuscript. AZ conceived and designed the study and critically reviewed the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Funding information

This work was supported by a grant from the Ministry of Education, Science and Technological Development, Republic of Serbia (Project No. 175035).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The entire study protocol was designed according to the Helsinki Declaration and approved by the local ethical committee (The Ethics committee of the Military Medical Academy; Ethics Committee reference no. 3000-1).

References

  1. 1.
    Nyström M, Mutanen M. Diet and epigenetics in colon cancer. World J Gastroenterol. 2009;15:257–63.CrossRefGoogle Scholar
  2. 2.
    Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013;8:e53916.CrossRefGoogle Scholar
  3. 3.
    Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6:9.CrossRefGoogle Scholar
  4. 4.
    Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011;22:259–65.Google Scholar
  5. 5.
    İclal G, Mehmet K, Yılmaz K, Müslüm A. Increased resistin serum concentrations in patients with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2013;5:189–93.CrossRefGoogle Scholar
  6. 6.
    Asgary S, SamsamShariat S, Ghorbani A, Keshvari M, Sahebkar A, Sarrafzadegan N. Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population. Diabetes Metab Syndr Clin Res Rev. 2015;9:266–70.CrossRefGoogle Scholar
  7. 7.
    Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–4.CrossRefGoogle Scholar
  8. 8.
    Riondino S, Roselli M, Palmirotta R, Della-Morte D, Ferroni P, Guadagni F. Obesity and colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol. 2014;20:5177–90.CrossRefGoogle Scholar
  9. 9.
    Feng Z, Zhang H. Resistin and cancer risk: a mini-review. Endocrinol Metabol Syndrome. 2011;S4:003.Google Scholar
  10. 10.
    Dalamaga M. Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med. 2014;8:107–18.CrossRefGoogle Scholar
  11. 11.
    Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control. 2015;26:257–68.CrossRefGoogle Scholar
  12. 12.
    Mihajlovic M, Gojkovic T, Vladimirov S, Miljkovic M, Stefanovic A, Vekic J, et al. Changes in lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and paraoxonase-1 activities in patients with colorectal cancer. Clin Biochem. 2019;63:32–8.CrossRefGoogle Scholar
  13. 13.
    Stevanovic M, Vekic J, Bogavac-Stanojevic N, Janac J, Stjepanovic Z, Zeljkovic D, et al. Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development. Biochem Med. 2018;28:503–13.CrossRefGoogle Scholar
  14. 14.
    Lu M, Zhan X. The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J. 2018;9:77–102.CrossRefGoogle Scholar
  15. 15.
    Golubnitschaja O, Costigliola V. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:14.CrossRefGoogle Scholar
  16. 16.
    Tarkowski A, Bjersing J, Shestakov A, Bokarewa M. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010;14:1419–31.CrossRefGoogle Scholar
  17. 17.
    Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J, et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab. 2014;19:484–97.CrossRefGoogle Scholar
  18. 18.
    Yang G, Fan W, Luo B, Xu Z, Wang P, Tang S, et al. Circulating resistin levels and risk of colorectal cancer: a meta-analysis. Biomed Res Int. 2016;2016:1–11.Google Scholar
  19. 19.
    Munjas J, Sopić M, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Anđelković K, Jelić-Ivanović Z. Association of adenylate cyclase-associated protein 1 with coronary artery disease. Eur J Clin Investig. 2017;47:659–66.CrossRefGoogle Scholar
  20. 20.
    Cheng T, Zhan X. Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J. 2017;8:51–60.CrossRefGoogle Scholar
  21. 21.
    Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper. EPMA J. 2016;7:23.CrossRefGoogle Scholar
  22. 22.
    Hashemi M, Bahari G, Tabasi F, Moazeni-Roodi A, Ghavami S. Association between rs1862513 and rs3745367 genetic polymorphisms of resistin and risk of cancer: a meta-analysis. Asian Pac J Cancer Prev. 2018;19:2709–16.Google Scholar
  23. 23.
    Vujovic A, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Spasic S, Kotur-Stevuljevic J, Jelic-Ivanovic Z. Comparison of two RNA isolation methods for determination of SOD1 and SOD2 gene expression in human blood and mononuclear cells. Indian J Biotechnol. 2013;12:468–74.Google Scholar
  24. 24.
    Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC, Chen YC, et al. Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 2018;37:589–600.CrossRefGoogle Scholar
  25. 25.
    Hsieh YY, Shen CH, Huang WS, Chin CC, Kuo YH, Hsieh MC, et al. Resistin-induced stromal cell-derived factor-1 expression through toll-like receptor 4 and activation of p38 MAPK/ NFκB signaling pathway in gastric cancer cells. J Biomed Sci. 2014;21:59.CrossRefGoogle Scholar
  26. 26.
    Zhang H, Zhou G. CAP1 (cyclase-associated protein 1) exerts distinct functions in the proliferation and metastatic potential of breast Cancer cells mediated by ERK. Sci Rep. 2016;6:25933.CrossRefGoogle Scholar
  27. 27.
    Xie S, Shen C, Zhou S, Xiong M, Tan M, Song X, et al. Role of adenylate cyclase-associated protein 1 in cancers. Int J Clin Exp Med. 2018;11:3086–99.Google Scholar
  28. 28.
    Ono S. The role of cyclase-associated protein in regulating actin filament dynamics–more than a monomer-sequestration factor. J Cell Sci. 2013;126:3249–58.CrossRefGoogle Scholar
  29. 29.
    Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286–90.CrossRefGoogle Scholar
  30. 30.
    Danese E, Montagnana M, Minicozzi AM, Bonafini S, Ruzzenente O, Gelati M, et al. The role of resistin in colorectal cancer. Clin Chim Acta. 2012;413:760–4.CrossRefGoogle Scholar
  31. 31.
    Song G, Wu X, Zhang P, Yu Y, Yang M, Jiao P, et al. High-density lipoprotein inhibits ox-LDL-induced adipokine secretion by upregulating SR-BI expression and suppressing ER stress pathway. Sci Rep. 2016;6:30889.CrossRefGoogle Scholar
  32. 32.
    Rosso LG, Lhomme M, Merono T, Sorroche P, Catoggio L, Soriano E, et al. Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. Atherosclerosis. 2014;237:652–60.CrossRefGoogle Scholar
  33. 33.
    Kunnari AM, Savolainen ER, Ukkola OH, Kesäniemi YA, Jokela MA. The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept. 2009;157:57–63.CrossRefGoogle Scholar
  34. 34.
    Ghaemmaghami S, Mohaddes S, Hedayati M, Mohammadi M, Dehbashi G. Resistin and visfatin expression in HCT-116 colorectal cancer cell line. Int J Mol Cell Med. 2013;2:143–50.Google Scholar
  35. 35.
    Munoz-Palomeque A, Guerrero-Ramirez MA, Rubio-Chavez LA, Rosales-Gomez RC, Lopez-Cardona MG, Barajas-Avila VH, et al. Association of RETN and CAP1 SNPs, expression and serum resistin levels with breast cancer in Mexican women. Genet Test Mol Biomarkers. 2018;22:209–17.CrossRefGoogle Scholar
  36. 36.
    Gordon S, Plüddemann A. Tissue macrophages: heterogeneity and functions. BMC Biol. 2017;15:53.CrossRefGoogle Scholar
  37. 37.
    Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–96.CrossRefGoogle Scholar
  38. 38.
    Janssens JP, Schuster K, Voss A. Preventive, predictive, and personalized medicine for effective and affordable cancer care. EPMA J. 2018;9:113–23.CrossRefGoogle Scholar
  39. 39.
    Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101:1286–91.CrossRefGoogle Scholar
  40. 40.
    Ning S, Wei W, Li J, Hou B, Zhong J, Xie Y, et al. Clinical significance and diagnostic capacity of serum TK1, CEA, CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients. J Cancer. 2018;9:494–501.CrossRefGoogle Scholar
  41. 41.
    Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H, et al. The G/G genotype of a resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004;75:678–86.CrossRefGoogle Scholar
  42. 42.
    Osawa H, Tabara Y, Ohashi J, Kawamura R, Onuma H, Makino H. Is rs34861192 or rs1862513 a more promising variant for determining plasma resistin in an aged Japanese population? Diabetologia. 2010;53:795–7.CrossRefGoogle Scholar
  43. 43.
    Onuma H, Tabara Y, Kawamura R, Ohashi J, Nishida W, Takata Y, et al. Dual effects of a RETN single nucleotide polymorphism (SNP) at −420 on plasma resistin: genotype and DNA methylation. J Clin Endocrinol Metab. 2017;102:884–92.CrossRefGoogle Scholar

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2019

Authors and Affiliations

  • Marija Mihajlovic
    • 1
    Email author
  • Ana Ninic
    • 1
  • Miron Sopic
    • 1
  • Milica Miljkovic
    • 1
  • Aleksandra Stefanovic
    • 1
  • Jelena Vekic
    • 1
  • Vesna Spasojevic-Kalimanovska
    • 1
  • Dejan Zeljkovic
    • 2
  • Bratislav Trifunovic
    • 2
    • 3
  • Zeljka Stjepanovic
    • 4
  • Aleksandra Zeljkovic
    • 1
  1. 1.Department of Medical Biochemistry, Faculty of PharmacyUniversity of BelgradeBelgradeSerbia
  2. 2.Clinic of General SurgeryMilitary Medical AcademyBelgradeSerbia
  3. 3.Faculty of Medicine of the Military Medical AcademyUniversity of DefenceBelgradeSerbia
  4. 4.Medigroup General HospitalBelgradeSerbia

Personalised recommendations